Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma

Australasian Journal of Dermatology

Volumn 58, Issue 3, 2017, Pages e109-e112

  Parakh, Sagun ^a,b   Nguyen, Rebecca ^a   Opie, Jacinta M ^a   Andrews, Miles C ^a,b  

^a AUSTIN HEALTH   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

bullous pemphigoid; immunotherapy; melanoma; programmed death 1 inhibition

Indexed keywords

B RAF KINASE; BETAMETHASONE DIPROPIONATE; CEFALEXIN; CORTICOSTEROID; DABRAFENIB; DACARBAZINE; DOXYCYCLINE; EMOLLIENT AGENT; FLUORODEOXYGLUCOSE F 18; IPILIMUMAB; MOMETASONE FUROATE; MORPHINE SULFATE; NICOTINAMIDE; PEMBROLIZUMAB; PREDNISOLONE; PREGABALIN; PROGRAMMED DEATH 1 LIGAND 1; TRAMETINIB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BACTEROIDES FRAGILIS; BASEMENT MEMBRANE; BLOOD CULTURE; BONE METASTASIS; BULLOUS PEMPHIGOID; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; CELL INFILTRATION; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CYTOREDUCTIVE SURGERY; DEBRIDEMENT; DECUBITUS; DISEASE ACTIVITY; DNA MUTATIONAL ANALYSIS; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DRY SKIN; EMISSION TOMOGRAPHY; ENTEROCOCCUS FAECALIS; EOSINOPHIL; ERYTHEMA; FATIGUE; FOURTH LUMBAR VERTEBRA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; LATE ONSET DISORDER; LUMBOSACRAL SPINE; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTATIC MELANOMA; PAPULE; PARAPLEGIA; PRURITUS; SEPSIS; SKIN BIOPSY; SKIN TOXICITY; SPINAL CORD METASTASIS; URTICARIA; WOUND INFECTION; CHEMICALLY INDUCED; MELANOMA; PATHOLOGY; SECONDARY; SKIN TUMOR; TIME FACTOR;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DRUG ERUPTIONS; HUMANS; MALE; MELANOMA; PEMPHIGOID, BULLOUS; SKIN NEOPLASMS; TIME FACTORS;

EID: 84969832915     PISSN: 00048380     EISSN: 14400960     Source Type: Journal    
DOI: 10.1111/ajd.12488     Document Type: Article

References (13)

1. Ribas A, Hodi FS, Kefford R et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J. Clin. Oncol. 2014; 32: 5s. LB9000.
2. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015; 372: 320–30.
3. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 2015; 372: 2521–32.
4. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16(8): 908–18. doi: 10.1016/S1470-2045(15)00083-2.
5. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012; 30: 2691–7.
6. Yancey KB. The pathophysiology of autoimmune blistering diseases. J. Clin. Investig. 2005; 115: 825–8.
7. Kardaun SH, Sekula P, Valeyrie-Allanore L et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br. J. Dermatol. 2013; 169: 1071–80.
8. Venning V, Taghipour K, Mohd Mustapa M et al. British Association of Dermatologists' guidelines for the management of bullous pemphigoid 2012. Br. J. Dermatol. 2012; 167: 1200–14.
9. Bolognia J, Jorizzo J, Schaffer J (eds). Dermatology, Volume 1, 3rd edn. Philadelphia, PA: Elsevier Saunders, 2012
10. Krenacs T, Kiszner G, Stelkovics E et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem. Cell Biol. 2012; 138: 653–67.
11. Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015; 51: 221–8.
12. Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014; 124: 687–95.
13. Carlos G, Anforth R, Chou S et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res. 2015; 25: 265–8.